R-MINE regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Mesna-Ifosfamide-Novantrone-Etoposide regimen
Overview
R-MINE regimen refers to a regimen consisting of rituximab, mesna, ifosfamide, mitoxantrone, and etoposide used to treat relapsed or refractory Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.[1][2]
Regimen
RRituximab
MMesna
IIfosfamide
NMitoxantrone (Novantrone)
EEtoposide
Indications
References
- ↑ 1.0 1.1 Fan Y, Huang ZY, Luo LH, Yu HF (2005). “[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin’s lymphoma]”. Ai Zheng. 24 (12): 1503–6. PMID 16351801.
- ↑ “NCI Thesaurus”.
- ↑ “NCI Thesaurus”.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
